Immunome, Inc.

IMNM · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders6.6%

Institutions106.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$6.94M	$9.04M	$14.02M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$224.11M	-$305.80M	-$109.53M	-$25.20M	-$12.26M
Operating income as a percentage of revenue.	-3228.8%	-3382.4%	-781.4%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$212.39M	-$292.96M	-$106.80M	-$24.70M	-$17.84M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.00	$-5.00	$-5.00	$-2.14	$-5.26
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.00	$-5.00	$-5.00	$-2.14	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$653.50M	$143.40M	$98.68M	$49.23M	$39.77M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$683.19M	$240.24M	$148.54M	$57.92M	–
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	$500000
Everything the company owes — debt, unpaid bills, and other obligations.	$48.84M	$59.08M	$28.66M	$9.74M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$634.34M	$181.16M	$119.88M	$48.19M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$190.92M	-$110.79M	-$7.57M	-$18.23M	-$12.13M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$9.69M	$7.17M	$831000	$79000	$586000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$200.60M	-$117.97M	-$8.40M	-$18.30M	-$12.72M

	You	Peer avg
Revenue Growth	–	-95.6%
ROE	-64.0%	-36.5%

Immunome, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison